GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF
Allergy Therapeutics PLC (OTCPK:AGYTF)
[1]
Significantly Overvalued[5]$ 0.44
Drug Manufacturers - Drug Manufacturers - Specialty & Generic
Market Cap: $ 219 Mil
Allergy Therapeutics PLC is a pharmaceutical products company. It develops therapies for allergy based diseases, having its primary market in Germany.
Valuation Rank
Score: 3 /10CurrentIndustry MedianHistorical Median
PE Ratio84.1723.3762.5
Forward P/EN/A17.07N/A
PB Ratio3.412.264.19
PS Ratio2.042.981.88
P/FCF28.0627.4530.38
Shiller P/EN/A27.57N/A
PEG RatioN/A2.08N/A
Valuation Analysis
% of Price
NCAV0.0511
Graham Number0.1227
Tangible Book0.1227
Median PS Value0.491
Price0.44
Dividend & Ownership
Dividend Yield(ttm) %N/A
Dividend Yield(forward) %N/A
PayoutN/A
Dividend Growth(5y) %N/A
Yield on Cost(5y) %N/A
Continuous Div. sinceN/A
Insider Ownership %N/A
Institution Ownership %5.78
Financial Strength
Score: 7 /10CurrentIndustry MedianHistorical Median
Cash-to-Debt3.611.113.61
Equity-to-Asset0.550.600.52
Interest Coverage8.2119.373.93
Piotroski F-Score556
Profitability Rank
Score: 5 /10CurrentIndustry MedianHistorical Median
Operating Margin %4.785.662.18
Net Margin %3.423.041.69
ROE %5.733.594.66
ROA %3.171.222.41
ROC (Joel Greenblatt) %17.857.218.85
Growth (Per Share)
10 Yr5 Yr1 Yr
Revenue Growth (%)16.37.8
EBITDA Growth (%)N/AN/A-36.8
Oprt. Income Growth (%)N/AN/A-50
EPS w/o NRI Growth (%)N/AN/A-63.6
Free Cash Flow Growth (%)N/AN/A-40
Book Value Growth (%)15.49.77.2
Quarterly
Jun19Dec19Jun20Dec20Jun21
Revenue3466357342
Net Income-920-1020-17
EPS-0.010.03-0.020.03-0.03
Revenue (YoY) %12.7316.82-0.0222.8224.16
Net Income (YoY) %-27.18147.85-42.9653.6394.48
EPS (YoY) %-30130.77-46.674592.86
Free Cash Flow-518-516-9
Cash & Equiv.3552466556
Current Assets5975699381
Short-Term Debt & CLO13332
Current Liabilities2120232226
Total Liabilities3948535455
Stockholders Equity4867557968
Warning Signs
SEVEREAsset Growth: faster than revenue growth
MEDIUMAltman Z-Score: Grey
MEDIUMLong-Term Debt: Issuing new debt
MEDIUMROIC vs. WACC: Return on invested capital is less than weighted average cost of capital.
Good Signs
GOODBeneish M-Score: Unlikely manipulator
As of 01-23-2022
* All financial numbers are in millions except for per share data, ratios and percentage change.
Gain % SP500 %
1W---5.75
1M-13.73-5.42
3M-11.65-3.10
6M76.001.47
YTD---7.79
1Y83.3315.50
3Y32.7719.94
5Y-0.4516.09
10Y11.3614.91
0.54
0.27
--
51539
25769.5
2012201320142015201620172018201920202021CurrentPerformance
0.270.260.740.440.810.390.40.340.150.240.54Highest Stock Price
0.150.150.160.240.450.230.250.10.080.120Lowest Stock Price
617814820026519617910896150219Market Cap
340.1471.7471.5498.2570.3592.2625.2669.7673.5676.7672Shares Outstanding-Diluted
38.7598.7575N/AAt LossAt LossAt Loss2812.7362.584.17PE Ratio
2.683.455.813.716.165.085.882.271.742.213.41PB Ratio
0.641.191.692.512.182.372.591.271.2122.04PS Ratio
7.6517.4122.2147.13-8.8698.68-34.239.735.1616.1616.11EV-to-EBITDA
2012201320142015201620172018201920202021TTMPer Share Data
0.190.130.150.140.120.140.150.140.150.180.17Revenue per Share
000---0.03-0.01-0.020.010.010.010Earnings per Share
0.010.0100.01-0.03-0-0.010.010.020.010.01Free Cash Flow per Share
----------------------Dividends per Share
0.040.040.050.080.060.050.040.070.080.090.09Tangible Book per Share
----0.220.150.190.140.130.170.160.210.4Median PS Value
0.060.040.06--------0.10.150.110.07Graham Number
2012201320142015201620172018201920202021TTMIncome Statement
64.260.97167.368.982.190.993.497.9118.3115.1Revenue
42.942.450.848.448.960.668.370.172.687.384.8Gross Profit
66.969.671.571.87173.975.175.174.273.873.7Gross Margin %
41.241.348.747.265.963.177.264.662.281.680.1Total Operating Expense
1.7121.1-17-2.4-8.95.610.45.74.7Operating Income
2.71.72.91.7-24.6-3-9.9610.64.84.1Operating Margin %
1.311.30.2-18.6-3.2-104.48.843.2Net Income
21.61.80.3-27-3.9-114.793.42.8Net Margin %
3.61.42.41.4-16.7-2.2-8.75.710.75.84.9EBIT
6.53.54.53.4-14.40.2-6.18.315.611.610.6EBITDA
9.84.35.20.4-38.4-7.8-2911.217.36.64.7ROE %
2.82.22.70.3-23.3-4.1-14.25.79.13.52.6ROA %
2012201320142015201620172018201920202021Jun21Balance Sheet
1.41.93.43333.228.320.734.846.356.556.5Cash & Equivalents
4.84.94.74.86.65.655.54.44.24.2Total Receivables
43.244.948.17980.573.267.886.8107.9123.5123.5Total Assets
2.20.40.10.40.40.50.90.92.82.52.5Short-Term Debt & CLO
0.2----2.24.43.83.22.212.413.213.2Long-Term Debt & CLO
20.522.222.525.337.434.937.239.253.155.555.5Total Liabilities
22.722.725.553.743.138.430.647.654.868.168.1Total Stockholders Equity
22.722.725.553.743.138.430.647.654.868.168.1Total Equity
2012201320142015201620172018201920202021TTMCashflow Statement
4.53.83.74.9-16.80.2-5.17.115.611.811Cash Flow from Operations
-2.4-1.8-1.9-4.2-2.1-2.5-3.3-4.2-3.1-3.7-3.7Cash Flow from Investing
----------------------Repurchase of Stock
-23.2------2.2-0.3-0.4-0.81.5-0.2-0.2Net Issuance of Debt
-4.30.2--31.317.8-0.2-0.412.1-0.5-2.9-2.8Cash Flow from Financing
-2.32.31.629.93.1-1.6-8.815.111.94.64Net Change in Cash
-2-1.3-1.6-1.7-1.8-2.2-2.9-3.9-3.2-3.6-3.6Capital Expenditure
2.52.52.13.1-18.6-2-83.212.48.27.5Free Cash Flow
Competitor
TickerCompanyFinancial
Strength
Profitability
Rank
Market Cap
($M)
PE RatioPS RatioNet
Margin %
ROA %ROE %
OTCPK:AGYTFAllergy Therapeutics PLC7521984.172.043.423.175.73
LSE:SARSareum Holdings PLC00191At Loss0.000.00-67.30-75.52
LSE:EAHEco Animal Health Group PLC8817022.291.235.484.796.69
LSE:DNLDiurnal Group PLC90134At Loss18.28-229.90-33.82-38.12
LSE:FUMFutura Medical PLC91127At Loss0.000.00-47.82-55.17
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Financial Strength[2] (Quarterly data, as of Jun. 2021) : Good (7/10)

0
1
2
3
4
5
6
7
8
9

Cash-to-Debt : 3.61

Cash-to-Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. A high ratio indicates that a company is better able to pay back its debt, and is thus able to take on more debt if necessary.


Equity-to-Asset : 0.55

Equity-to-Asset ratio is calculated as total stockholders equity divided by its total assets. Equity-to-Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity-to-Asset ratio (more leveraged) may have higher ROE % because of the leverage.


Debt-to-Equity : 0.23

A high Debt-to-Equity ratio generally means that a company has been aggressive in financing its growth with debt.


Piotroski F-Score : 5

The Piotroski F-Score is used to determine the strength of a firm's financial position, with 9 being the best and 0 being the worst.

0
1
2
3
4
5
6
7
8
9


WACC : 9.51% vs ROIC : 7.89%

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business.


Dividend Yield : 0.00%

Dividend yield is a way to measure how much cash flow you are getting for each dollar invested in an equity position.

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Profitability[3] (Annual data, as of Jun. 2021) : Fair (5/10)

0
1
2
3
4
5
6
7
8
9

Revenue : $42 Mil vs Net Income : $-17 Mil

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. Net Income is a company's total profit. Net income is calculated by taking revenues and adjusting for the cost of doing business, depreciation, interest, taxes and other expenses.


Cash & Equivalents : $56 Mil vs Long-Term Debt* : $13 Mil

Cash & equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash. Long-Term Debt* consists of loans and obligations lasting over one year.


Operating Margin % : -38.77%

Operating margin % measures how much profit a company makes on a dollar of sales. Operating Margin % is calculated as Operating Income divided by Revenue.


EPS without NRI : $-0.03

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.


Dividends per Share : $0.00

Dividends per Share is the amount of dividends that the shareholders of a company receive on a per-share basis. It is calculated using the total dividends paid out to shareholders over one fiscal year and the number of shares outstanding.


Free Cash Flow per Share : $-0.01

Free Cash flow per Share is the amount of Free cash flow per outstanding share of the company's stock.

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Valuation (Quarterly data, as of Jun. 2021)

These valuation metrics should give you a sense of reasonable prices, but be careful with them. Always seek to understand why a valuation is changing over time.


Valuation Chart (Current stock price : $0.44)


PE Ratio without NRI : 62.50

The price-to-earnings ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.


PB Ratio : 2.21

The price-to-book ratio measures the valuation of the stock relative to the underlying asset of the company.


PS Ratio : 2.00

The price-to-sales ratio is a valuation ratio that compares a company’s stock price to its revenues. The price-to-sales ratio is an indicator of the value placed on each dollar of a company’s sales or revenues.


Price-to-Free-Cash-Flow : 27.78

Price-to-free-cash-flow is very similar to the valuation metric of price-to-operating-cash-flow but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.


EV-to-EBIT : 32.26

Enterprise value of a company divided by its trailing 12 months earnings before interest and taxes (EBIT).

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Valuation Bands

In these charts the 10-year valuation bands of the price-to-earnings ratio (PE Ratio), price-to-book ratio (PB Ratio), price-to-sales ratio (PS Ratio) and price-to-operating-cash-flow ratio (POCF) are drawn together with the historical stock prices. For example, the upper line of the PE band is where the stock price would have been if it were always traded at the maximum PE ratio of the past 10 years. The lower line of the PE band is where the stock price would have been if it were always traded at the lowest PE ratio of the past 10 years. It is always better if the stock price is close to the lower line, which indicates a lower valuation.


Historical Price and PE Band


Historical Price and PS Band


Historical Price and PB Band


Historical Price and Price-to-Operating-Cash-Flow (POCF) Band

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Warning Signs

GuruFocus conducted a thorough checkup using a checklist of 32 items that cover the areas of financial strength, profitability, growth, and valuation of each company. The purpose of Warning Signs is to warn you that the company may have red flags in certain areas, helping to avoid overlooking them. These warning signs do not necessarily mean you should not invest in the stock. But you should be aware of them before you invest.


Severe Warning Signs

Asset Growth : faster than revenue growth

If a company builds asset at 8.9% a year, faster than its revenue growth rate of 6.3% over the past 5 years, it means that the company may be getting less efficent.

Good Signs

Beneish M-Score : Unlikely manipulator

Beneish M-Score -2.9 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

Medium Warning Signs

Altman Z-Score : Grey

Altman Z-score of 2.41 is in grey area. The implies that the company is in some kind of financial stress. If it is below 1.8, the company may faces bankrupcy risk.

Long-Term Debt : Issuing new debt

Allergy Therapeutics PLC has been issuing new debt. Over the past 3 years, it issued GBP 0.449 million of debt. But overall, its debt level is acceptable.

ROIC vs. WACC : Return on invested capital is less than weighted average cost of capital.

Companys's return on invested capital is less than weighted average cost of capital. It might not be capital efficient
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Competitive Comparison


5 Year Price Change Comparison


Financial Strength

CompanyFinancial StrengthCash-to-DebtEquity-to-AssetDebt-to-EquityInterest CoveragePiotroski F-ScoreAltman Z-ScoreBeneish M-ScoreWACC %ROIC %
LSE:DNLDiurnal Group PLC9/10No Debt0.900.00No Debt213.40-2.485.32-219.09
LSE:FUMFutura Medical PLC9/10No Debt0.950.00No Debt30.002.5324.76-567.50
LSE:STXShield Therapeutics PLC9/10No Debt0.970.00No Debt621.469.307.42-45.18
OTCPK:AGYTFAllergy Therapeutics PLC7/103.610.550.238.2152.41-2.909.517.89
LSE:SISScience in Sport PLC7/1011.400.710.020.0074.34-3.027.90-5.53
LSE:VLGVenture Life Group PLC6/100.570.710.2012.8472.710.002.091.20
LSE:N4PN4 Pharma PLC0/10No Debt0.960.000.0020.00-4.86-9.50-1496.12
LSE:PXSProvexis PLC0/10No Debt1.300.00No Debt642.850.0012.22-305.05
LTS:0RNSRapid Nutrition PLC0/100.340.410.86N/A22.605.241.319.69
LSE:SARSareum Holdings PLC0/10No Debt0.910.00No Debt30.002.89-4.70-2105.32

Profitability

CompanyProfitability RankOperating
Margin %
Net Margin %ROE %ROA %Price-to-Free-Cash-FlowROC (Joel Greenblatt) %3-Year Revenue Growth %3-Year EBITDA Growth %3-Year EPS w/o NRI Growth %
OTCPK:AGYTFAllergy Therapeutics PLC5/104.783.425.733.1728.0617.854.700.000.00
LSE:SISScience in Sport PLC3/10-11.62-9.66-4.73-3.5585.63-31.095.200.0044.70
LSE:VLGVenture Life Group PLC3/107.981.280.590.420.0010.33-9.507.700.00
LSE:FUMFutura Medical PLC1/100.000.00-55.17-47.820.00-3327.10-100.0033.1032.10
LSE:STXShield Therapeutics PLC1/10-625.40-668.91-33.50-31.750.00-1306.63145.700.0051.00
LSE:DNLDiurnal Group PLC0/10-265.39-229.90-38.12-33.820.00-820.56217.5034.9035.20
LSE:N4PN4 Pharma PLC0/100.000.00-59.94-57.040.00-1553.780.0027.6029.10
LSE:PXSProvexis PLC0/10-63.05-59.08-21.53-29.440.00-514.770.000.000.00
LTS:0RNSRapid Nutrition PLC0/1025.6025.6016.977.000.0010.12-9.70-12.60-43.30
LSE:SARSareum Holdings PLC0/100.000.00-75.52-67.300.00-4025.200.000.000.00

Valuation

CompanyPE RatioPB RatioPS RatioPrice-to-Intrinsic-Value-Projected-FCFPrice-to-Intrinsic-Value-DCF (Earnings Based)Price-to-Median-PS-ValuePrice-to-Peter-Lynch-Fair-ValuePrice-to-Graham-NumberEarnings Yield (Joel Greenblatt) %Forward Rate of Return (Yacktman) %
LSE:DNLDiurnal Group PLCAt Loss2.6118.280.000.000.000.000.00-14.770.00
LSE:FUMFutura Medical PLCAt Loss7.220.000.000.000.000.000.00-3.630.00
LSE:N4PN4 Pharma PLCAt Loss2.270.001.700.000.000.000.00-43.29-166.48
LSE:SARSareum Holdings PLCAt Loss41.500.000.000.000.000.000.00-1.230.00
LSE:SISScience in Sport PLCAt Loss1.923.706.850.000.000.000.00-2.990.00
LSE:STXShield Therapeutics PLCAt Loss1.5825.000.000.000.000.000.00-20.920.00
LTS:0RNSRapid Nutrition PLC13.332.293.480.000.000.000.000.805.27-7.27
LSE:VLGVenture Life Group PLC82.000.741.720.750.000.000.004.563.010.00
OTCPK:AGYTFAllergy Therapeutics PLC84.173.412.044.400.001.100.003.673.11-5.66
LSE:PXSProvexis PLCN/A8.000.000.000.000.000.000.40-1.810.00
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Peter Lynch Chart[4]

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Per Share Data



Per Share Data

Jun06
Jun07
Jun08
Jun09
Jun10
Jun11
Jun12
Jun13
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
TTM Fiscal Period
0.66
0.62
0.74
0.75
0.2
0.21
0.19
0.13
0.15
0.14
0.12
0.14
0.15
0.14
0.15
0.18
0.17
Revenue per Share
-0.15
-0.6
-0.41
-0.14
0.02
0
0.02
0.01
0.01
0.01
-0.03
--
-0.01
0.01
0.02
0.02
0.02
EBITDA per Share
-0.17
-0.62
-0.44
-0.16
0.01
-0.01
0.01
0
0.01
0
-0.03
-0
-0.01
0.01
0.02
0.01
0.01
EBIT per Share
-0.17
-0.57
-0.49
-0.24
0
-0.01
0
0
0
--
-0.03
-0.01
-0.02
0.01
0.01
0.01
0
Earnings per Share (Diluted)
-0.17
-0.57
-0.49
-0.24
0
-0.01
0
0
0
--
-0.03
-0.01
-0.02
0.01
0.01
0.01
0
EPS without NRI
-0.24
-0.46
-0.63
-0.17
--
-0.02
0.02
--
0.01
--
-0.06
--
-0.01
--
0.02
0.01
0.02
Owner Earnings per Share (TTM)
-0.27
-0.52
-0.53
-0.04
--
-0.02
0.01
0.01
0
0.01
-0.03
-0
-0.01
0.01
0.02
0.01
0.01
Free Cash Flow per Share
-0.21
-0.44
-0.46
-0.01
0.01
-0.01
0.01
0.01
0.01
0.01
-0.03
--
-0.01
0.01
0.02
0.02
0.02
Operating Cash Flow per Share
0.54
0.14
0.06
--
0.02
0.01
0
0.01
0.01
0.06
0.06
0.05
0.04
0.06
0.07
0.09
0.09
Cash per Share
0.74
0.21
-0.27
-0.46
0.02
0.01
0.06
0.06
0.06
0.1
0.07
0.07
0.05
0.08
0.09
0.1
0.1
Book Value per Share
0.67
0.13
-0.36
-0.53
0
-0.01
0.04
0.04
0.05
0.08
0.06
0.05
0.04
0.07
0.08
0.09
0.09
Tangible Book per Share
--
0.05
0.62
0.61
0.06
0.06
0.01
0
--
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.02
Total Debt per Share
--
--
--
--
0.2
0.11
0.15
0.19
0.36
0.36
0.45
0.33
0.3
0.17
0.15
0.23
0.44
Month End Stock Price

Ratios

Jun06
Jun07
Jun08
Jun09
Jun10
Jun11
Jun12
Jun13
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
TTM Fiscal Period
-23.52
-119
--
--
--
-93.72
9.79
4.32
5.2
0.42
-38.38
-7.8
-29.04
11.23
17.25
6.59
4.72
ROE %
--
--
--
--
--
-9.37
3.65
1.25
0.9
0.11
-6.23
-1.54
-4.94
4.95
9.91
2.98
1.68
ROE % Adjusted to Book Value
-19.24
-78.64
-85.53
-47.14
2.19
-9.31
2.76
2.23
2.7
0.26
-23.29
-4.13
-14.2
5.68
9.07
3.5
2.61
ROA %
-26.94
-143
--
--
Neg. E
--
21.56
6.09
7
0.52
-45.64
-9.5
-36.15
13.41
19.56
7.34
5.2
Return-on-Tangible-Equity
-21.48
-88.15
-100
-55.97
2.54
-10.71
3.26
2.62
3.11
0.3
-25.77
-4.57
-15.71
6.19
9.67
3.7
2.75
Return-on-Tangible-Asset
-154
-467
-232
-84.31
18.26
-9.27
18.2
6.97
11.19
6.21
-86.59
-14.36
-58.55
33.83
45.92
20.21
15.82
ROC (Joel Greenblatt) %
-23.2
-117
-129
-89.14
17.18
-5.26
11.46
4.48
6.71
2.6
-25.7
-3.79
-16.87
10.01
14.26
6.36
4.99
ROCE %
-61.8
-181
-89.94
-6.22
-45.52
0.68
6.05
3.4
3.72
0.47
-45.5
-7.68
-24.84
10.71
18.65
7.98
6.63
ROIC %
10.64
7.04
13.88
12.59
8.13
8.52
7.36
4.6
8.13
5.67
5.88
3.83
3.71
3.67
7.7
6.63
9.51
WACC %
0.89
6.06
14.07
10.45
7.78
11.66
23.19
43.84
197
25.1
11.24
6.37
10.22
7.12
6.88
4.46
4.3
Effective Interest Rate on Debt %
72.35
60.89
64.98
64.08
72.6
68.18
66.88
69.57
71.51
71.83
71
73.85
75.11
75.07
74.17
73.79
73.67
Gross Margin %
-27.07
-101
-48.67
-4.05
5.66
0.28
2.65
1.7
2.88
1.68
-24.64
-2.96
-9.85
5.96
10.62
4.78
4.11
Operating Margin %
-26.2
-90.34
-65.43
-31.16
1.44
-6.41
1.99
1.61
1.77
0.25
-26.95
-3.87
-11.02
4.7
9.03
3.42
2.76
Net Margin %
-41.39
-82.78
-70.74
-5.72
0.01
-7.86
3.92
4.1
2.99
4.67
-26.95
-2.41
-8.76
3.39
12.71
6.92
6.5
FCF Margin %
--
0.25
-2.29
-1.33
3.01
5.78
0.1
0.02
0
0.05
0.11
0.11
0.13
0.07
0.28
0.23
0.23
Debt-to-Equity
0.86
0.36
-0.49
-1.05
0.13
0.07
0.53
0.51
0.53
0.68
0.54
0.52
0.45
0.55
0.51
0.55
0.55
Equity-to-Asset
--
0.09
1.11
1.4
0.4
0.4
0.06
0.01
0
0.03
0.06
0.06
0.06
0.04
0.14
0.13
0.13
Debt-to-Asset
0.14
0.64
1.49
2.05
0.87
0.93
0.47
0.49
0.47
0.32
0.47
0.48
0.55
0.45
0.49
0.45
0.45
Liabilities-to-Assets
53.14
53
84.94
96.96
110
99.14
92.55
96.21
109
76.15
61.35
78.9
96.79
90.7
74.56
75.41
69.79
Gross-Profit-to-Asset %
0.73
0.87
1.31
1.51
1.52
1.45
1.38
1.38
1.53
1.06
0.86
1.07
1.29
1.21
1.01
1.02
0.95
Asset Turnover
30.61
24.47
22.23
19.77
18.19
38.31
44.97
29.02
24.46
25.67
30.33
27.1
21.25
20.65
18.48
13.15
24.31
Days Sales Outstanding
87.64
112
117
87.7
132
154
139
85.67
80.3
82.35
80.44
68.89
64.01
74.39
57.91
40.25
104
Days Payable
178
150
181
175
221
185
187
194
183
206
196
174
172
185
178
164
166
Days Inventory
121
63.2
86.18
107
107
69
93.25
137
127
150
146
133
129
131
138
137
86.87
Cash Conversion Cycle
2.05
2.43
2.01
2.09
1.65
1.98
1.95
1.88
2
1.77
1.86
2.09
2.12
1.97
2.06
2.22
2.19
Inventory Turnover
0.28
0.39
0.35
0.36
0.27
0.32
0.33
0.3
0.28
0.28
0.29
0.26
0.25
0.25
0.26
0.26
0.26
COGS-to-Revenue
0.14
0.16
0.17
0.17
0.17
0.16
0.17
0.16
0.14
0.16
0.16
0.13
0.12
0.13
0.13
0.12
0.12
Inventory-to-Revenue
0.09
0.12
0.09
0.05
0.04
0.03
0.03
0.02
0.02
0.03
0.03
0.03
0.03
0.04
0.03
0.03
0.03
Capex-to-Revenue
--
--
--
--
0.74
10.76
1.16
1.23
0.76
1.52
--
--
--
0.71
0.31
0.64
0.75
Capex-to-Operating-Income
* All financial numbers are in millions except for per share data, ratios and percentage change. When Return-on-Tangible-Equity displays Neg. E, it means the the tangible equity is negative.
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Financial Satement



Income Statement

Jun06
Jun07
Jun08
Jun09
Jun10
Jun11
Jun12
Jun13
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
TTM Fiscal Period
43.46
51.18
60.95
61.8
60.19
67.35
64.2
60.9
70.99
67.34
68.9
82.12
90.89
93.43
97.88
118
115
Revenue
12.02
20.02
21.35
22.2
16.49
21.43
21.26
18.53
20.22
18.97
19.99
21.47
22.62
23.29
25.28
31
30.32
Cost of Goods Sold
31.45
31.16
39.6
39.6
43.7
45.92
42.94
42.37
50.77
48.37
48.92
60.65
68.26
70.14
72.59
87.27
84.8
Gross Profit
72.35
60.89
64.98
64.08
72.6
68.18
66.88
69.57
71.51
71.83
71
73.85
75.11
75.07
74.17
73.79
73.67
Gross Margin %
--
22.49
25.25
24.37
23.84
46.07
37.98
37.4
43.84
42.49
43.06
52.07
56.75
56.51
55.67
64.34
63.05
Selling, General, & Admin. Expense
17.64
50.38
32.02
8.67
3.26
2.71
3.26
3.93
5.01
4.86
23.04
11.9
21.3
8.81
7.32
18.07
17.8
Research & Development
25.57
10.22
11.99
9.06
13.19
-3.05
--
-0
-0.13
-0.11
-0.21
-0.9
-0.84
-0.75
-0.79
-0.8
-0.78
Other Operating Expense
43.21
83.09
69.27
42.1
40.3
45.73
41.24
41.33
48.72
47.24
65.89
63.08
77.21
64.57
62.2
81.62
80.07
Total Operating Expense
-11.76
-51.93
-29.66
-2.5
3.41
0.19
1.7
1.04
2.05
1.13
-16.98
-2.43
-8.95
5.57
10.4
5.65
4.73
Operating Income
-27.07
-101
-48.67
-4.05
5.66
0.28
2.65
1.7
2.88
1.68
-24.64
-2.96
-9.85
5.96
10.62
4.78
4.11
Operating Margin %
1.01
1.29
0.39
0.05
0.01
0
0.01
0.17
0.29
0.23
0.26
0.19
0.2
0.13
0.33
0.15
0.15
  Interest Income
-0.01
-0.26
-3.87
-5.3
-2.64
-2.18
-2.6
-0.62
-0.52
-0.34
-0.42
-0.29
-0.43
-0.25
-0.63
-0.69
-0.67
  Interest Expense
1
1.03
-9.14
-8.5
-2.75
-3.94
-2.59
-0.45
-0.23
-0.11
-0.16
-0.09
-0.22
-0.12
-0.3
-0.52
-0.51
Net Interest Income
-0.62
-0.31
-0.97
-7.72
-0.83
-0
1.89
0.23
0.02
0
--
0
0
--
--
--
0
Other Income (Expense)
-11.39
-51.21
-39.77
-18.72
-0.17
-3.75
1
0.82
1.83
1.02
-17.14
-2.52
-9.17
5.44
10.1
5.13
4.22
Pre-Tax Income
--
4.98
-0.1
-0.53
1.04
-0.57
0.28
0.16
-0.58
-0.85
-1.43
-0.65
-0.85
-1.05
-1.27
-1.08
-1.04
Tax Provision
--
9.72
-0.26
-2.85
605
-15.09
-28.59
-19.66
31.64
83.49
-8.36
-25.94
-9.24
19.24
12.55
21.08
24.75
Tax Rate %
-11.39
-46.23
-39.88
-19.25
0.87
-4.31
1.28
0.98
1.25
0.17
-18.57
-3.18
-10.02
4.39
8.83
4.05
3.17
Net Income (Continuing Operations)
-11.39
-46.23
-39.88
-19.25
0.87
-4.31
1.28
0.98
1.25
0.17
-18.57
-3.18
-10.02
4.39
8.83
4.05
3.17
Net Income
-26.2
-90.34
-65.43
-31.16
1.44
-6.41
1.99
1.61
1.77
0.25
-26.95
-3.87
-11.02
4.7
9.03
3.42
2.76
Net Margin %
-0.17
-0.57
-0.49
-0.24
0
-0.01
0
0
0
--
-0.03
-0.01
-0.02
0.01
0.01
0.01
0
EPS (Basic)
-0.17
-0.57
-0.49
-0.24
0
-0.01
0
0
0
--
-0.03
-0.01
-0.02
0.01
0.01
0.01
0
EPS (Diluted)
66.12
81.95
81.95
81.99
306
323
340
472
472
498
570
592
625
670
673
677
672
Shares Outstanding (Diluted Average)
-11.38
-50.95
-35.9
-13.42
2.47
-1.57
3.59
1.44
2.36
1.36
-16.72
-2.23
-8.74
5.7
10.73
5.82
4.89
EBIT
1.46
1.9
2.28
2.15
2.11
2.75
2.94
2.08
2.18
2.01
2.37
2.48
2.69
2.65
4.9
5.8
5.68
Depreciation, Depletion and Amortization
-9.92
-49.05
-33.62
-11.27
4.58
1.18
6.53
3.52
4.53
3.37
-14.35
0.24
-6.06
8.34
15.63
11.61
10.57
EBITDA

Cashflow Statement

Jun06
Jun07
Jun08
Jun09
Jun10
Jun11
Jun12
Jun13
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
TTM Fiscal Period
-12.39
-52.24
-30.63
-8.35
2.15
-3.75
1
0.82
1.83
1.02
-17.14
-2.52
-9.17
5.44
10.1
5.13
4.22
Net Income From Continuing Operations
1.46
1.9
2.28
2.15
2.11
2.75
2.94
2.08
2.18
2.01
2.37
2.48
2.69
2.65
4.9
5.8
5.68
Depreciation, Depletion and Amortization
-0.77
0.41
0.34
-0.39
-0.17
-4.42
2
-3.36
2.86
-0.7
-0.52
1.29
4.39
-2.36
4.62
3
3.22
  Change In Receivables
-1.68
-2.5
-1.78
-0.3
-1.35
0.12
0.42
1.19
-1.06
-0.66
-0.83
0.43
-1.77
-0.69
-0.88
-1.57
-1.57
  Change In Inventory
-1.98
10.58
-10.31
7.06
0.02
-2.9
-1
1.16
-1.54
1.68
-0.59
1.05
-2.34
0.21
-3
0.77
0.79
  Change In Other Working Capital
-4.42
8.48
-11.74
6.36
-1.49
-7.2
1.43
-1.01
0.26
0.32
-1.94
2.77
0.28
-2.85
0.74
2.2
2.44
Change In Working Capital
--
--
--
--
--
--
--
--
--
--
-0.12
-0.9
-0.84
-0.75
-0.79
--
-0.38
Deferred Tax
--
0.74
0.71
0.43
0.28
0.24
0.2
0.28
0.3
0.64
0.47
0.9
1.32
1.74
0.99
0.9
0.89
Stock Based Compensation
1.41
4.94
1.43
-1.31
-0.53
4.67
-1.09
1.6
-0.9
0.87
-0.46
-2.5
0.67
0.87
-0.31
-2.25
-1.82
Cash Flow from Others
-13.94
-36.18
-37.96
-0.72
2.51
-3.29
4.48
3.77
3.68
4.86
-16.82
0.23
-5.06
7.1
15.63
11.78
11.03
Cash Flow from Operations
-4.04
-6.18
-5.15
-2.82
-2.51
-1.86
-0.67
-1.03
-1.52
-1.7
-1.75
-1.92
-2.67
-3.56
-2.83
-3.59
-3.55
Purchase Of Property, Plant, Equipment
--
--
--
--
--
-1.2
--
--
--
-2.11
--
--
--
--
--
--
-- Purchase Of Business
--
-0.38
-0.5
-0.48
-0.47
-0.51
-0.48
-0.55
-0.48
-0.43
-0.37
-0.33
-0.49
-0.51
-0.29
-0.27
-0.27
Purchase Of Investment
--
--
--
--
--
-0.14
-1.29
-0.24
-0.04
-0.02
--
-0.29
-0.24
-0.37
-0.35
--
0
Net Intangibles Purchase And Sale
--
1.29
0.39
0.05
0.01
0
0.01
0.03
0.12
0.1
-0
0.05
0.06
0.19
0.33
0.16
0.16
Cash From Other Investing Activities
-4.04
-5.27
-5.26
-3.25
-2.97
-3.71
-2.44
-1.79
-1.91
-4.15
-2.12
-2.49
-3.33
-4.25
-3.14
-3.7
-3.66
Cash Flow from Investing
35.54
0.05
0.07
0.14
38.02
0
19.62
0.23
--
31.28
15.59
0.04
0
13.43
0
0.01
0.01
Issuance of Stock
--
6.64
40.1
5.03
33.15
14.63
11.94
--
--
--
2.35
0.1
0.14
--
2.36
0.88
0.84
  Issuance of Debt
--
-1.35
-3.62
-5.01
-63.94
-13.39
-35.18
--
--
--
-0.12
-0.38
-0.53
-0.83
-0.82
-1.06
-1.04
  Payments of Debt
--
5.3
36.48
0.02
-30.79
1.24
-23.24
--
--
--
2.23
-0.28
-0.39
-0.83
1.54
-0.19
-0.19
Net Issuance of Debt
-1.35
--
--
--
--
--
-0.63
--
--
--
--
--
--
-0.51
-2.08
-2.67
-2.63
Other Financing
34.19
5.34
36.55
0.17
7.23
1.24
-4.25
0.23
--
31.28
17.81
-0.24
-0.39
12.1
-0.54
-2.85
-2.82
Cash Flow from Financing
--
--
--
--
-0.06
0.13
-0.05
0.08
-0.13
-2.13
4.26
0.86
0.01
0.15
-0.03
-0.58
-0.58
Effect of Exchange Rate Changes
16.2
-36.11
-6.68
-3.8
6.71
-5.63
-2.27
2.28
1.63
29.86
3.13
-1.64
-8.76
15.09
11.92
4.64
3.98
Net Change in Cash
-4.04
-6.18
-5.15
-2.82
-2.51
-2
-1.96
-1.27
-1.56
-1.72
-1.75
-2.21
-2.9
-3.93
-3.19
-3.59
-3.55
Capital Expenditure
-17.99
-42.36
-43.11
-3.54
0.01
-5.29
2.52
2.5
2.12
3.14
-18.57
-1.98
-7.96
3.17
12.44
8.19
7.48
Free Cash Flow
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Financial Satement


Balance Sheet

Jun06
Jun07
Jun08
Jun09
Jun10
Jun11
Jun12
Jun13
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
TTM Fiscal Period
44.02
11.32
4.51
--
6.68
1.7
1.4
1.95
3.43
33.02
33.25
28.33
20.66
34.78
46.26
56.48
56.48
  Cash And Cash Equivalents
44.02
11.32
4.51
--
6.68
1.7
1.4
1.95
3.43
33.02
33.25
28.33
20.66
34.78
46.26
56.48
56.48
Cash, Cash Equivalents, Marketable Securities
3.28
3.58
3.84
2.85
3.15
10.99
4.83
4.85
4.66
4.81
6.64
5.55
5.03
5.54
4.37
4.15
4.15
  Accounts Receivable
3.28
3.58
3.84
2.85
3.15
10.99
4.83
4.85
4.66
4.81
6.64
5.55
5.03
5.54
4.37
4.15
4.15
Total Receivables
1.99
3.39
3.46
2.69
3.06
3.56
3.14
2.94
3.14
2.61
2.28
2.11
2.88
2.97
3.6
4.16
4.16
  Inventories, Raw Materials & Components
3.74
4.87
7.11
6.07
6.61
5.08
4.39
3.52
5.32
4.57
4.46
3.55
3.69
3.61
4.63
3.84
3.84
  Inventories, Work In Process
1
1.5
0.85
1.07
0.51
2.85
2.81
2.86
2.49
3.33
4.18
3.92
5.14
5.35
4.46
7.2
7.2
  Inventories, Finished Goods
0
--
--
--
--
-0
--
--
--
--
--
--
--
0
0
-0
-0
  Inventories, Other
6.74
9.76
11.43
9.82
10.18
11.49
10.34
9.32
10.95
10.51
10.93
9.58
11.71
11.93
12.68
15.2
15.2
Total Inventories
3.32
3.25
2.45
2.78
1.86
--
3.69
6.29
5
4.29
2.61
4.5
3.73
6.85
5.74
5.31
5.31
Other Current Assets
57.36
27.92
22.23
15.45
21.87
24.17
20.27
22.42
24.05
52.63
53.43
47.96
41.13
59.09
69.05
81.15
81.15
Total Current Assets
14.76
17.27
17.57
17.15
16.07
--
23.81
24.86
27.96
27.52
27.9
24.81
28.15
30.26
33.75
41.09
41.09
  Machinery, Furniture, Equipment
0.5
0.52
4.74
3.7
6.38
14.28
1.96
1.87
1.91
4.05
4.29
4.1
4.55
3.86
14.85
16.24
16.24
  Other Gross PPE
15.26
17.79
22.31
20.85
22.45
14.28
25.77
26.73
29.87
31.57
32.19
28.91
32.7
34.12
48.6
57.32
57.32
Gross Property, Plant and Equipment
-8.55
-6.88
-8.79
-9.08
-9.25
--
-14.02
-15.35
-17.98
-17.94
-18.46
-16.52
-19.28
-19.57
-23.05
-29.67
-29.67
  Accumulated Depreciation
6.71
10.91
13.52
11.77
13.2
14.28
11.75
11.38
11.9
13.63
13.73
12.39
13.43
14.55
25.55
27.65
27.65
Property, Plant and Equipment
5.82
6.87
6.96
5.92
4.96
7.14
7.15
6.06
6.38
7.79
7.61
6.99
6.58
6.13
5.93
6.67
6.67
Intangible Assets
9.19
4.57
4.85
4.19
3.69
4.25
3.87
3.97
4.2
4.64
4.64
4.34
4.53
4.35
4.34
4.68
4.68
  Goodwill
0
2.01
2.83
2.99
2.98
4.04
4
5.05
5.73
4.92
5.75
5.88
6.71
7.04
7.39
8.08
8.08
Other Long Term Assets
12.53
19.78
23.31
20.68
21.14
25.46
22.89
22.49
24.01
26.34
27.08
25.25
26.71
27.72
38.87
42.4
42.4
Total Long-Term Assets
69.89
47.7
45.55
36.13
43.01
49.63
43.16
44.91
48.05
78.97
80.51
73.22
67.84
86.81
108
124
124
Total Assets
3.08
9.17
4.54
6.12
5.83
12.24
3.97
4.73
4.17
4.39
4.42
3.69
4.25
5.25
2.77
4.06
4.06
  Accounts Payable
--
--
--
--
--
--
1.06
0.83
1
0.8
2.03
1.97
2.95
2.38
5.56
5.27
5.27
  Total Tax Payable
1.92
1.2
1.37
2.44
2.65
--
0.21
1.11
0.49
0.52
0.2
0.24
0.28
0.17
0.09
0.04
0.04
  Other Current Payables
5.01
10.37
5.91
8.56
8.48
12.24
5.24
6.67
5.66
5.71
6.64
5.9
7.47
7.79
8.42
9.36
9.36
Accounts Payable & Accrued Expense
--
--
4.76
19.07
1.64
--
2.22
0.45
0.08
0.39
0.42
0.5
0.86
0.88
1.04
1.35
1.35
  Short-Term Debt
--
--
--
--
--
--
--
--
--
--
--
--
--
--
1.8
1.11
1.11
  Short-Term Capital Lease Obligation
--
--
4.76
19.07
1.64
--
2.22
0.45
0.08
0.39
0.42
0.5
0.86
0.88
2.83
2.46
2.46
Short-Term Debt & Capital Lease Obligation
4.11
11.23
5.26
8
4.63
5.83
4.59
4.7
5.21
5.46
10.72
11.55
11.13
12.7
11.56
13.74
13.74
Other Current Liabilities
9.11
21.6
15.92
35.64
14.75
18.07
12.05
11.81
10.95
11.56
17.78
17.95
19.46
21.37
22.81
25.57
25.57
Total Current Liabilities
--
4.3
46
31.51
15.65
20.03
0.15
--
--
2.23
4.36
3.76
3.21
2.21
3.66
3.44
3.44
  Long-Term Debt
--
--
--
--
--
--
--
--
--
--
--
--
--
--
8.75
9.77
9.77
  Long-Term Capital Lease Obligation
--
4.3
46
31.51
15.65
20.03
0.15
--
--
2.23
4.36
3.76
3.21
2.21
12.41
13.21
13.21
Long-Term Debt & Capital Lease Obligation
--
0.25
-2.29
-1.33
3.01
5.78
0.1
0.02
0
0.05
0.11
0.11
0.13
0.07
0.28
0.23
0.23
Debt-to-Equity
--
4.34
4.57
4.62
5.28
6.67
7.34
9.63
10.86
10.52
14.45
12.32
13.76
14.89
16.93
15.84
15.84
PensionAndRetirementBenefit
0.44
0.38
1.24
2.3
1.59
1.39
0.93
0.71
0.73
0.97
0.84
0.82
0.79
0.75
0.97
0.86
0.86
Other Long-Term Liabilities
0.44
9.01
51.8
38.43
22.52
28.1
8.42
10.35
11.59
13.72
19.65
16.9
17.75
17.85
30.31
29.91
29.91
Total Long-Term Liabilities
9.55
30.61
67.73
74.06
37.27
46.16
20.47
22.16
22.54
25.28
37.44
34.85
37.21
39.21
53.12
55.48
55.48
Total Liabilities
0.17
0.18
0.18
0.15
0.47
0.52
0.65
0.65
0.71
0.87
0.85
0.77
0.79
0.81
0.8
0.9
0.9
Common Stock
-75.53
-130
-167
-159
-145
-163
-156
-154
-167
-155
-162
-147
-162
-151
-141
-151
-151
Retained Earnings
61.2
65.95
65.17
54.33
86.71
95.15
105
105
115
142
145
131
136
143
141
158
158
Additional Paid-In Capital
74.49
81.23
79.95
66.39
63.27
70.35
72.68
71.12
76.94
65.15
58.58
52.98
55.54
55.16
54.48
59.91
59.91
Other Stockholders Equity
60.34
17.09
-22.18
-37.93
5.74
3.47
22.69
22.75
25.51
53.69
43.07
38.37
30.63
47.6
54.8
68.07
68.07
Total Stockholders Equity
60.34
17.09
-22.18
-37.93
5.74
3.47
22.69
22.75
25.51
53.69
43.07
38.37
30.63
47.6
54.8
68.07
68.07
Total Equity
0.86
0.36
-0.49
-1.05
0.13
0.07
0.53
0.51
0.53
0.68
0.54
0.52
0.45
0.55
0.51
0.55
0.55
Equity-to-Asset
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Valuation Ratios



Valuation Ratios

Jun06
Jun07
Jun08
Jun09
Jun10
Jun11
Jun12
Jun13
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
TTM Fiscal Period
N/A
N/A
N/A
N/A
57.5
At Loss
38.75
98.75
75
N/A
At Loss
At Loss
At Loss
28
12.73
62.5
84.17
PE Ratio
N/A
N/A
N/A
N/A
57.5
At Loss
38.75
98.75
75
N/A
At Loss
At Loss
At Loss
28
12.73
62.5
84.17
PE Ratio without NRI
--
--
--
--
--
--
7.5
--
36
--
--
--
--
--
7.5
23
25.25
Price-to-Owner-Earnings
--
--
--
--
11.11
10
2.68
3.45
5.81
3.71
6.16
5.08
5.88
2.27
1.74
2.21
3.41
PB Ratio
--
--
--
--
66.67
--
3.95
4.63
7.66
4.34
7.5
6.23
7.5
2.62
1.95
2.45
3.67
Price-to-Tangible-Book
--
--
--
--
--
--
15.5
32.92
50
54.69
--
--
--
35
9.33
27.78
28.06
Price-to-Free-Cash-Flow
--
--
--
--
19.17
--
9.69
19.75
30
36.46
--
--
--
17.5
7.37
20.83
21.04
Price-to-Operating-Cash-Flow
2.78
3.81
0.74
0.3
0.86
1.09
0.64
1.19
1.69
2.51
2.18
2.37
2.59
1.27
1.21
2
2.04
PS Ratio
2.43
3.67
1.5
1.12
1.05
1.32
0.78
1.01
1.42
2.36
1.83
2.08
2.28
0.87
0.82
1.59
1.58
EV-to-Revenue
-10.65
-3.83
-2.72
-6.16
13.85
75.41
7.65
17.41
22.21
47.13
-8.8
699
-34.23
9.73
5.16
16.16
16.11
EV-to-EBITDA
-9.28
-3.68
-2.54
-5.17
25.67
-56.46
13.92
42.62
42.74
117
-7.56
-76.47
-23.71
14.25
7.51
32.26
32.16
EV-to-EBIT
-10.78
-27.17
-39.37
-19.34
3.9
-1.77
7.18
2.35
2.34
0.85
-13.23
-1.31
-4.22
7.02
13.32
3.1
3.11
Earnings Yield (Joel Greenblatt) %
-3.03
-6.19
-47.86
-59.49
-123
-81.43
--
--
-1.33
-5.61
--
--
--
--
--
--
-5.66
Forward Rate of Return (Yacktman) %

Valuation and Quality

Jun06
Jun07
Jun08
Jun09
Jun10
Jun11
Jun12
Jun13
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
TTM Fiscal Period
--
--
--
--
62.15
34.18
61.04
77.87
148
200
265
196
179
108
95.59
150
219
Market Cap
--
--
--
--
72.76
52.52
62
76.37
144
170
237
172
162
76.46
64.58
109
179
Enterprise Value
--
--
--
--
0.2
0.11
0.15
0.19
0.36
0.36
0.45
0.33
0.3
0.17
0.15
0.23
0.44
Month End Stock Price
0.42
-0.24
-0.77
-0.9
-0.1
-0.14
-0.05
-0.05
-0.05
0.01
-0.01
-0.01
-0.03
-0.01
-0.01
--
-- Net Cash per Share
0.58
-0.03
-0.56
-0.71
-0.05
-0.07
--
--
--
0.05
0.03
0.02
0.01
0.03
0.02
0.04
0.04
Net Current Asset Value
0.49
-0.14
-0.67
-0.81
-0.07
-0.1
-0.03
-0.03
-0.02
0.03
0.01
--
-0.01
0.01
--
0.02
0.02
Net-Net Working Capital
--
-1.32
-2.53
-2.72
-0.4
-0.19
-0.37
-0.21
-0.1
0.1
0.05
0.01
--
0.02
0.04
0.06
0.06
Intrinsic Value: Projected FCF
--
--
--
--
--
--
--
--
0.22
0.15
0.19
0.14
0.13
0.17
0.16
0.21
0.4
Median PS Value
--
--
--
--
0.01
--
0.06
0.04
0.06
--
--
--
--
0.1
0.15
0.11
0.07
Graham Number
-0.11
-1.33
-2.71
-3.33
0.03
-0.01
-0.02
-0.02
-0.05
0.28
0.27
0.14
0.08
0.12
0.15
0.19
0.37
Earnings Power Value (EPV)
8.8
-2.3
-5.85
-6.19
-2.07
-2.27
-1.62
-1.36
-0.12
3.28
0.37
2.07
1.57
1.11
1.18
2.42
2.41
Altman Z-Score
2
1
5
4
8
2
6
7
9
6
1
6
4
7
5
5
5
Piotroski F-Score
-2.36
-3.87
-3.03
-4.99
-2.41
-0.66
-3.05
-2.75
-2.78
-2.7
-2.33
-2.72
-2.93
-2.5
-3.08
-2.9
-2.9
Beneish M-Score
0.34
0.14
0.5
0.28
0.45
0.51
0.48
0.49
0.49
0.49
0.19
0.18
0.19
0.24
0.27
0.25
0.21
Scaled Net Operating Assets
9.44
-10.02
7.35
-42.29
3.06
5.39
-1.77
-2.22
-1.06
-0.69
0.46
-1.25
-2.41
1.78
-3.38
-3.26
-3.4
Sloan Ratio %
6.29
1.29
1.4
0.43
1.48
1.34
1.68
1.9
2.2
4.55
3
2.67
2.11
2.77
3.03
3.17
3.17
Current Ratio
5.56
0.84
0.68
0.16
0.79
0.7
0.82
1.11
1.2
3.64
2.39
2.14
1.51
2.21
2.47
2.58
2.58
Quick Ratio
4.83
0.52
0.28
--
0.45
0.09
0.12
0.16
0.31
2.86
1.87
1.58
1.06
1.63
2.03
2.21
2.21
Cash Ratio
--
--
--
--
1.29
0.09
0.65
1.68
3.93
3.33
--
--
--
21.85
16.49
8.21
7.01
Interest Coverage
--
--
--
--
0.35
0.14
0.27
0.26
0.74
0.44
0.81
0.39
0.4
0.34
0.15
0.24
0.54
Highest Stock Price
--
--
--
--
0.17
0.05
0.15
0.15
0.16
0.24
0.45
0.23
0.25
0.1
0.08
0.12
0
Lowest Stock Price
-30.18
--
--
-0.51
-277
--
-30.94
-0.73
--
-35.58
-6.02
-0.84
-0.35
-6.71
-0.18
-2.25
-2.25
Shares Buyback Ratio %
--
--
--
--
-61.17
--
-32.14
-0.29
--
-15.63
-5.88
-0.02
--
-12.42
--
--
-- Buyback Yield %
0.77
-5.02
19.23
1.34
-73.87
5.58
-9.13
-31.75
17.05
-10.6
-10.37
14.88
4.32
-3.45
3.57
20.69
14.09
YoY Rev. per Sh. Growth
-177
-228
13.81
51.54
101
-567
129
-50
50
-100
--
84.85
-240
141
85.71
-53.85
-85.71
YoY EPS Growth
-369
-299
31.55
66.59
111
-73.33
375
-63.16
42.86
-30
-457
100
--
220
91.67
-26.09
-40
YoY EBITDA Growth
--
--
--
--
--
--
--
--
--
-5.99
--
--
--
--
--
--
-- 5-Year EBITDA Growth Rate
66.12
81.95
81.95
81.99
293
311
327
453
452
475
570
592
595
633
636
639
641
Shares Outstanding (Basic Average)
81.95
81.95
81.95
82.37
311
311
407
410
410
556
589
594
596
636
637
652
644
Shares Outstanding (EOP)
--
--
--
--
--
--
--
--
--
0.53
0.38
-0.14
-0.04
-0.77
1.69
825
875
Beta
06/30/12
09/13/13
09/13/13
09/24/14
10/20/15
09/26/16
10/19/17
10/23/18
10/22/19
11/10/20
10/07/21
  Filing Date
06/30/12
09/13/13
09/24/14
10/20/15
09/26/16
10/19/17
10/23/18
10/22/19
11/10/20
10/07/21
10/07/21
  Restated Filing Date
09/19/11
09/17/12
09/16/13
09/22/14
09/21/15
09/26/16
09/28/17
09/26/18
09/25/19
09/23/20
09/23/21
  Earnings Release Date
267
334
362
374
394
373
356
349
345
358
440
506
497
518
600
599
599
Number of Employees
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Allergy Therapeutics PLC (OTCPK:AGYTF)
www.gurufocus.com/stock/OTCPK:AGYTF

Explanation

1. Predictability Rank

GuruFocus Predictability Rank is a proprietary ranking of the consistency of a business. We rank the predictability of companies based on the consistency of their revenue per share and EBITDA (earnings before interest, tax, depreciation and amortization) per share over the past 10 fiscal years. Our study found that there is a strong correlation between the stock performance and the predictability of a business. Over the long term, companies with higher predictability also have better stock performance.

The rank is from 1-star to 5-star, with 5-star as the best.

2. Financial Strength

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

  1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
  2. Debt to revenue ratio. The lower, the better.
  3. Altman Z-Score.

The rank is from 1 to 10, with 10 as the highest.

A Financial Strength rank of 8 or above indicates good financial strength; between 4-7 indicates fair financial strength; 3 or below means poor financial strength.

3. Profitability Rank

GuruFocus Profitability Rank indicates how profitable a company is and how likely it is that the company's business will stay that way. It is based on these factors:

  1. Operating Margin %.
  2. Piotroski F-Score.
  3. Trend of the Operating Margin percentage (five-year average). A company with an uptrend in profit margin will have a higher rank.
  4. Consistency of the profitability.
  5. Predictability Rank.

The rank is from 1 to 10, with 10 as the highest.

A Profitability Rank of 8 or above indicates good profitability; between 4-7 indicates fair profitability; 3 or below means poor profitability.

4. Peter Lynch Chart

In Peter Lynch's excellent book, "One Up on Wall Street," he used many charts to illustrate the valuation of stocks. “A quick way to tell if a stock is overpriced is to compare the price line to the earnings line. If you bought familiar growth companies – such as Shoney’s, The Limited, or Marriott – when the stock price fell well below the earnings line, and sold them when the stock price rose dramatically above it, the chances are you’d do pretty well.”

The original Peter Lynch Chart does have limitations due to the right side price scale is pre-set at 15 times the earnings scale on the left side. When the stock price and earnings line coincide, the price-to-earnings ratio is always 15 times. Instead of using the fixed PE Ratio of 15, our approach is using 15-year historical median PE without NRI Ratio for each stock.

The Peter Lynch Chart with earnings line at median PE without NRI ratio works well for the companies with steady growth and earnings trends, or the stalwarts, as coined by Lynch. These companies tend to be found in sectors such as consumer staples, healthcare, and utilities, where the consumption of the product or service is relatively independent of economic conditions. It does not work well with the sectors that are cyclical: industrials, chemicals, durable goods, and so forth.

5. GF Value

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

  1. Possible Value Trap, Think Twice
  2. Significantly Overvalued
  3. Modestly Overvalued
  4. Fairly Valued
  5. Modestly Undervalued
  6. Significantly Undervalued
There is only a sufficient margin of safety when the stock is undervalued.

Disclaimer

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.